Your browser doesn't support javascript.
loading
Heterostructure Nanozyme with Hyperthermia-Amplified Enzyme-Like Activity and Controlled Silver Release for Synergistic Antibacterial Therapy.
Zhang, Meng; Yue, Wenhui; Ma, Weishuai; Wang, Xiaoning; Xu, Yuanhong; Li, Aihua.
Afiliación
  • Zhang M; Institute of Biomedical Engineering, College of Life Science, Qingdao University, Qingdao, 266071, P. R. China.
  • Yue W; Institute of Biomedical Engineering, College of Life Science, Qingdao University, Qingdao, 266071, P. R. China.
  • Ma W; Institute of Biomedical Engineering, College of Life Science, Qingdao University, Qingdao, 266071, P. R. China.
  • Wang X; College of Materials Science and Engineering, Qingdao University, Qingdao, 266071, P. R. China.
  • Xu Y; Institute of Biomedical Engineering, College of Life Science, Qingdao University, Qingdao, 266071, P. R. China.
  • Li A; College of Materials Science and Engineering, Qingdao University, Qingdao, 266071, P. R. China.
Adv Healthc Mater ; : e2401602, 2024 Jun 20.
Article en En | MEDLINE | ID: mdl-38900390
ABSTRACT
Heterostructure nanozymes as antibiotic-free antimicrobial agents exhibit great potential for multidrug-resistant (MDR) bacterial strains elimination. However, realization of heterostructure antimicrobials with enhanced interfacial interaction for synergistically amplified antibacterial therapy is still a great challenge. Herein, oxygen-vacancy-enriched glucose modified MoOx (G-MoOx) is exploited as a reducing agent to spontaneously reduce Ag (I) into Ag (0) that in situ grows onto the surface of G-MoOx. The resultant Ag doped G-MoOx (Ag/G-MoOx) heterostructure displays augmenting photothermal effect and NIR-enhanced oxidase-like activity after introducing Ag nanoparticles. What's more, NIR hyperthermia accelerate Ag+ ions release from Ag nanoparticles. Introduction of Ag greatly enhances antimicrobial activities of Ag/G-MoOx against MDR bacteria, especially the hybrid loading with 1 wt% Ag NPs exhibiting antibacterial efficacy up to 99.99% against Methicillin-resistant Staphylococcus aureus (MRSA, 1×106 CFU mL-1).
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Adv Healthc Mater Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Adv Healthc Mater Año: 2024 Tipo del documento: Article